Cargando…

A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma

PURPOSE: Consolidation/maintenance therapy induces deep remission in patients with multiple myeloma (MM); however, the most suitable regimen has been under investigation. The combination therapy with bortezomib, lenalidomide and dexamethasone (VRD) is a powerful regimen for relapsed/refractory as we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibata, Soushi, Sato, Tsutomu, Kuroda, Hiroyuki, Nagamachi, Yasuhiro, Iyama, Satoshi, Fujimi, Akihito, Kamihara, Yusuke, Konuma, Yuichi, Yoshida, Masahiro, Tatekoshi, Ayumi, Hashimoto, Akari, Horiguchi, Hiroto, Ono, Kaoru, Murase, Kazuyuki, Takada, Kohichi, Miyanishi, Koji, Kobune, Masayoshi, Hirayama, Yasuo, Kato, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083756/ https://www.ncbi.nlm.nih.gov/pubmed/27738809 http://dx.doi.org/10.1007/s00280-016-3163-y

Ejemplares similares

Narrow-Band Ultraviolet B Phototherapy Ameliorates Acute Graft-Versus-Host Disease of the Intestine by Expansion of Regulatory T Cells
por: Hashimoto, Akari, et al.
Publicado: (2016)

Isoform D of vascular endothelial growth factor in systemic capillary leak syndrome: a case report
por: Ibata, Soushi, et al.
Publicado: (2016)

Efficacy of Enteral Supplementation Enriched with Glutamine, Fiber, and Oligosaccharide on Mucosal Injury following Hematopoietic Stem Cell Transplantation
por: Iyama, Satoshi, et al.
Publicado: (2014)

High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma
por: Ibata, Soushi, et al.
Publicado: (2018)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
por: Hashimoto, Akari, et al.
Publicado: (2014)

Radiation-Induced Leiomyosarcoma of the Prostate after Brachytherapy for Prostatic Adenocarcinoma
por: Horiguchi, Hiroto, et al.
Publicado: (2014)

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

miR-7977 inhibits the Hippo-YAP signaling pathway in bone marrow mesenchymal stromal cells
por: Yoshida, Masahiro, et al.
Publicado: (2019)

Small molecule CP-31398 induces reactive oxygen species-dependent apoptosis in human multiple myeloma
por: Arihara, Yohei, et al.
Publicado: (2017)

A novel strategy inducing autophagic cell death in Burkitt's lymphoma cells with anti-CD19-targeted liposomal rapamycin
por: Ono, K, et al.
Publicado: (2014)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma
por: Kamihara, Yusuke, et al.
Publicado: (2016)

Stromal cells expressing hedgehog-interacting protein regulate the proliferation of myeloid neoplasms
por: Kobune, M, et al.
Publicado: (2012)

Multiple Myeloma with Hyperammonemia Treated with Novel Agents: A Case Series of Three Patients
por: Nakamura, Hajime, et al.
Publicado: (2022)

Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells
por: Okagawa, Yutaka, et al.
Publicado: (2016)

Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment
por: Takada, Kohichi, et al.
Publicado: (2019)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
por: Nagashima, Kana, et al.
Publicado: (2020)

Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells
por: Iijima, Kazutaka, et al.
Publicado: (2021)

Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using a Fucose-Bound Nanoparticle Approach
por: Yoshida, Makoto, et al.
Publicado: (2012)

Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report
por: Takada, Kohichi, et al.
Publicado: (2019)

BH3 profiling discriminates the anti-apoptotic status of 5-fluorouracil-resistant colon cancer cells
por: Ishikawa, Kazuma, et al.
Publicado: (2019)

Efficacy of combination therapy with dexmedetomidine for benzodiazepines-induced disinhibition during endoscopic retrograde cholangiopancreatography
por: Ikeda, Yuki, et al.
Publicado: (2020)

Bortezomib/lenalidomide: Interstitial pneumonitis and peripheral neuropathy: case report
Publicado: (2020)

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
por: Hayasaka, Naotaka, et al.
Publicado: (2019)

Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer
por: Nakamura, Hajime, et al.
Publicado: (2020)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma
por: Zhou, Liang
Publicado: (2022)

Trastuzumab-Based Combination Chemotherapy in Patients with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Carcinoma ex Pleomorphic Adenoma
por: Arihara, Yohei, et al.
Publicado: (2018)

Acute Abdomen and Adrenal Swelling as the First Manifestations of TAFRO Syndrome
por: Fujimi, Akihito, et al.
Publicado: (2022)

Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
por: Win, Hninyee, et al.
Publicado: (2020)

Morphological Transformation of Myeloma Cells into Multilobated Plasma Cell Nuclei within 7 Days in a Case of Secondary Plasma Cell Leukemia That Finally Transformed as Anaplastic Myeloma
por: Fujimi, Akihito, et al.
Publicado: (2017)

DPP8 is a novel therapeutic target for multiple myeloma
por: Sato, Tsutomu, et al.
Publicado: (2019)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone
por: Yasui, Taku, et al.
Publicado: (2020)

Fucosylated TGF-β receptors transduces a signal for epithelial–mesenchymal transition in colorectal cancer cells
por: Hirakawa, M, et al.
Publicado: (2014)

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
por: Salwender, Hans, et al.
Publicado: (2019)

Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
por: Murase, Kazuyuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8qjln2l4mjds6sm4dt70ca0f1h